



EVH PROJECT

The project has the scope to provide EU with a self sustainable and independent ability to discover, develop and manufacture vaccines and monoclonal antibodies against infectious diseases of epidemic and pandemic potential.

The EVH project contributes to the **development of an agreed set of pandemic-prototype vaccines and scalable technologies** through a consortium including leading EU organisations directly involved in vaccine development and in charge of pandemic preparedness in their own countries, **ensuring effective coordination of national vaccine research programs**. EVH aligns with **the current international consensus on pandemic-vaccine development**, leveraging insights from existing prototypes to enable the rapid selection and deployment of the most suitable vaccine candidates in an emerging pandemic.


From prototype design to clinical applications, the EVH drives innovation, enhances clinical evaluation capacities, and coordinate efforts with manufacturers while optimizing the digitalization of vaccine design and distribution processes. EVH aims thus not only to create a reactive R&D system and knowledge hub linking powerful leading research institutions, but also initiate vaccine-development projects, refining relevant processes and procedures within its framework. The focus is on a select group of pathogens deemed critical for pandemic preparedness.

EVH STRATEGY

EVH is organised around **4 Pillars**, each supporting key activities and infrastructures of the vaccine development pipeline:

-  **Pillar 1 – Discovery**, led by FBS
-  **Pillar 2 – Preclinical Studies**, led by Institut Pasteur
-  **Pillar 3 – Clinical Studies**, led by Vaccinopolis
-  **Pillar 4 – Regulation & Manufacturing**, led by DZIF & ZEPAL.

In the event of pandemic, each pillar will set up and implement the platforms necessary for rapid vaccine development. EVH will engage and reinforce the complete ecosystem of European industry and academia, promoting collaborations and the exchange of know-how and projects.



EVH FACTS:

Topic: EU4H-2024-PJ-01-1

Total project cost: €169.992.330

EC contribution: €101.995.398

Duration: 4 years (1st March 2025-28th February 2029)

Coordinator Entity: Sclavo Vaccines Association (IT)

Partners: 11 Beneficiaries, 12 Affiliated Entities and 1 Associated Partner from 7 European countries

Contact: evhproject@sclavo.org

EVH PARTNERSHIP

Beneficiaries:



Sclavo Vaccines Association - SVA (IT)



Fondazione Biotechnopolo di Siena - FBS (IT)



Institut Pasteur - IP (FR)



Universiteit Antwerpen - Vaccinopolis (BE)



Deutsches Zentrum für Infektionsforschung - DZIF (DE)



Bundesinstitut für Impfstoffe und Biomedizinische Arzneimittel - ZEPAL (DE)



Academisch Ziekenhuis Leiden - LUMC (NL)



Université libre de Bruxelles - ULB (BE)



Folkhelseinstituttet - NIPH (NO)



Università degli Studi di Siena - UNISI (IT)



Instituto de Biologia Experimental e Tecnologica - iBET (PT)

Affiliated Entities:

Fondazione Biotechnopolo di Siena:

- Istituto Zooprofilattico Sperimentale delle Venezie (IT)

Institut Pasteur:

- Infrastructure Nationale en Biologie et Santé– Commissariat à l'énergie atomique et aux énergies alternatives (FR)
- Institut national de la santé et de la recherche médicale (FR)

Deutsches Zentrum für Infektionsforschung:

- Philipps Universität Marburg (DE)
- Helmholtz Zentrum München (DE)
- Helmholtz Centre for Infection Research (DE)
- Ludwig-Maximilians-Universität München (DE)
- Stiftung Tierärztliche Hochschule Hannover (DE)
- Technische Universität München (DE)
- Universitätsklinikum Köln (AÖR) (DE)
- Universitätsklinikum Hamburg Eppendorf (DE)
- Eberhard Karls Universität Tübingen (DE)

Associated partner:

- Pasteur Network (FR) (IP Associated partner)



"Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them"



EVH KEY ACTIVITIES

- Develop and implement a **pandemic vaccines readiness plan** for Europe
- Develop **pandemic vaccine candidates** for agreed pathogens **up to Phase 2 clinical trials**, including through relevant in vitro and in vivo models.
- Organise and optimise **the clinical evaluation of candidate vaccines** including in Phases I and II and the appropriate and supportive use of controlled infection facilities to speed up clinical development.
- Ensure **rapid delivery** of vaccine candidates for trial and mass production to manufacturing partners
- Set up shared, ready-to-use and scalable state-of-the-art technology platforms covering all phases of vaccine development with a focus on high-yield and rapidly adaptable production systems.
- Prepare and support technology transfers among EU partners and other eligible entities as part of the **creation of a centre of shared knowledge** for pandemic-relevant vaccine development.
- Prepare and perform **stress tests of pandemic vaccine production**, including on critical supply-chain element
- Prepare relevant **master clinical trial protocols** combining its activities to reach out to clinical trial capacities/networks and at scale production initiatives at national and European levels
- Implement a **pandemic planning platform** operating in the most cost-effective way



Co-funded by the
European Union

EUROPEAN VACCINES HUB FOR PANDEMIC READINESS

Web site: europeanvaccineshub.eu

Social contacts:  

Email: evhproject@sclavo.org